investors
Dr. Lalonde: From two years and 25 scientists to a few scientists for a few months
21 views
Dr. Lalonde: From two years and 25 scientists to a few scientists for a few months
"When I started out in 2004, that was the early days of enzyme engineering while we were still developing the tools at that point. One of the projects we worked on was Lipitor [...] I think it was $14 billion a year revenue. [...] The challenges with those kind of programs was that it was two years and 25 scientists to do one enzyme. It was a big, big spend. Now, with Invizyne, it's a few scientists for few months that can do an enzyme. So it'really a couple of orders of magnitude reduction in the amount of R&D because of the the tools have gotten so much better. [...] All these things have brought down the cost of R&D and increased the target." ~ states synthetic biology key opinion leader, Dr. James J. Lalonde, in an interview.
You can see the full interview here:
Invizyne IPO - KOL Call with Dr. James J. Lalonde (July 17, 2024)
#biomanufacturing #nextgenbiomanufacturing #cellfree #enzymes #biochemistry #biochemicals #synbio #syntheticbiology #synbiobeta #biosynthesis #simplepath #scalablebiochemistry #scalable #energytransition #endocannabinoids #cannabinoids #sustainableaviationfuel #SAF #greentech #cleantech
"When I started out in 2004, that was the early days of enzyme engineering while we were still developing the tools at that point. One of the projects we worked on was Lipitor [...] I think it was $14 billion a year revenue. [...] The challenges with those kind of programs was that it was two years and 25 scientists to do one enzyme. It was a big, big spend. Now, with Invizyne, it's a few scientists for few months that can do an enzyme. So it'really a couple of orders of magnitude reduction in the amount of R&D because of the the tools have gotten so much better. [...] All these things have brought down the cost of R&D and increased the target." ~ states synthetic biology key opinion leader, Dr. James J. Lalonde, in an interview.
You can see the full interview here:
Invizyne IPO - KOL Call with Dr. James J. Lalonde (July 17, 2024)
#biomanufacturing #nextgenbiomanufacturing #cellfree #enzymes #biochemistry #biochemicals #synbio #syntheticbiology #synbiobeta #biosynthesis #simplepath #scalablebiochemistry #scalable #energytransition #endocannabinoids #cannabinoids #sustainableaviationfuel #SAF #greentech #cleantech
